carvedilol + doxorubicin

Carvedilol + doxorubicin is a combination of two pharmaceutical agents used together primarily in the context of cancer therapy. Doxorubicin is an anthracycline antineoplastic agent widely used for its potent anticancer activity, but it is associated with significant risk of cardiotoxicity due to the generation of reactive oxygen species and mitochondrial dysfunction in cardiac tissue. Carvedilol is a non-selective beta-adrenergic blocker with additional alpha-1 blocking and antioxidant properties, often investigated for its potential to protect against doxorubicin-induced cardiotoxicity. The combination has been studied mainly to assess whether carvedilol can mitigate the adverse cardiac effects caused by doxorubicin during chemotherapy[1][4]. While some studies suggest that carvedilol may help preserve left ventricular function and reduce markers of myocardial injury when administered alongside doxorubicin, other research indicates limited or no clear benefit at certain biochemical or molecular endpoints[2][3][4].